Research programme: beta-catenin/lef-1 inhibitors - Novartis/University of Cologne

Drug Profile

Research programme: beta-catenin/lef-1 inhibitors - Novartis/University of Cologne

Alternative Names: CGP049090; PKF-115584

Latest Information Update: 19 Jul 2010

Price : $50

At a glance

  • Originator Novartis; University of Cologne
  • Class Small molecules
  • Mechanism of Action Beta catenin inhibitors; Wnt signalling pathway inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Preclinical Chronic lymphocytic leukaemia

Most Recent Events

  • 21 Apr 2010 Pharmacodynamics data from a preclinical trial in Chronic lymphocytic leukaemia presented at the 101st Annual Meeting of the American Association for Cancer Research (AACR-2010)
  • 16 Apr 2008 Preclinical pharmacodynamics data presented at the 99th Annual Meeting of the American Association for Cancer Research (AACR-2008)
  • 08 May 2007 Preclinical trials in Chronic lymphocytic leukaemia in Germany (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top